A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial

The primary study hypotheses for the COPE-AKI study are: compared to usual care, patients randomized to a multimodal intervention will have increased odds of more hospital-free days through 90 days (primary) and lower rates of major adverse kidney events (MAKE) at 180 days, lower rates of recurrent AKI at 180 days, and greater improvements in patient-reported outcomes over 90 days (secondary).

The primary outcome is hospital-free days through 90 days of follow up, defined as 90 minus the number of calendar days in the hospital as either an inpatient or on observation status, based on the determination made by the corresponding hospital. Key secondary outcomes include: rates of MAKE (measured at 90, 180, and 365 days), rates of recurrent AKI (90, 180, and 365 days), and 4 patient-report outcomes: global health related quality of life, AKI-specific health related quality of life, provider interactions, and social support (30, 90, 180, 365 days).

A multimodal process-of-care intervention that includes 1) study physician oversight and follow up care recommendations at the time of hospital discharge; 2) involvement of a nurse navigator to provide kidney-disease related education, coordinate care, and assess symptoms; and 3) pharmacist-led medication reconciliation and review. Participants in the usual care arm will be provided information about their kidney disease, nephrotoxins to be avoided, and the importance of follow up with a physician will be emphasized.

Inclusion criteria

• Aged ≥ 18 years
• Kidney Disease Improving Global Outcomes (KDIGO) Stage 2/3 AKI with evidence of persistent AKI (defined as meeting Stage 2+ AKI for 2 consecutive days with serum creatinine concentration measurements >12 hours apart)

Exclusion criteria

• AKI due to primary glomerulonephritis, renal vasculitis, or thrombotic microangiopathy
• Diagnosis of end-stage kidney disease (ESKD) at the time of admission, defined as:

• Baseline estimated glomerular filtration rate (eGFR) <15 mL/min/1.73m2
• Previous kidney transplant recipient
• On chronic dialysis
• Acute urinary obstruction with rapid kidney function improvement following relief of obstruction
• Index hospitalization involving nephrectomy
• Index hospitalization involving solid organ transplant or stem cell/bone marrow transplant
• Continued dialysis dependence at time of discharge
• Previous (within 6 months) or new referral to a nephrologist for care specifically for:

• Previous or new diagnosis of glomerulonephritis
• Primary electrolyte imbalance disorders unrelated to AKI (e.g., syndrome of inappropriate antidiuretic hormone secretion, Bartter syndrome)
• Active treatment for acute interstitial nephritis
• Non-kidney end-organ failure:

• Class IV congestive heart failure
• Decompensated cirrhosis with Model For End-Stage Liver Disease (MELD) > 30 or those with a diagnosis of hepatorenal syndrome by the clinical teams
• End-stage pulmonary disease (advanced stage chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
• Metastatic malignancy or malignancy requiring active treatment (chemotherapy, immunotherapy), such as multiple myeloma
• Primary goal of care is palliation: life expectancy <6 months
• Pregnancy
• Vulnerable populations

• Persons incarcerated
• Persons institutionalized
• Inability to provide informed consent

a. Impaired cognition as demonstrated by the Brief Confusion Assessment Method (bCAM)

• Concurrent enrollment in a separate greater than minimal risk interventional trial
• Inability to participate in either in-person or remote visits

a. Inability to participate as determined by the research team at time of discharge based on disposition (vs uniform decision across site about exclusion based on SNF)

• Discharge to long-term acute care facility or other hospital-based location